US › Healthcare

GRI Bio Inc. (GRI)

US · Healthcare · Biotechnology

$1.84+1.66%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-1.6M

EPS

$-0.91

EPS estimate

$-1.20

EPS came in at -0.91 against a street estimate of -1.20 — a beat of 24.2%.

Key statistics

Market cap

$4.2M

Forward P/E

0.0

P/B

0.40

Book value

$4.70

EPS (TTM)

$-2.83

52-week high

$64.12

52-week low

$1.36

50-day MA

$1.74

200-day MA

$6.10

Beta

-0.55

Analyst view

Analysts rate GRI Bio Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $18.50.

Shareholding

Insiders

0.38%

Institutions

4.28%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.84%
Citadel Advisors Llc	0.61%
UBS Group AG	0.40%
Tower Research Capital LLC	0.05%
BlackRock Inc	0.00%
SBI Securities Co Ltd	0.00%
Danske Bank A/S.	0.00%
Bank of America Corp	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GRI Bio Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.